Ultragenyx Pharmaceutical Inc. (RARE): restructuring charge — Ultragenyx Q4 rev $207M (+25%), net loss $129M; restructures 10% headcount; UX111 gets IRL

Ultragenyx Pharmaceutical Inc.

2025-FY EPS reported -$5.83 revenue$673,000,000

Full year 2025 total revenue $673M (+20% YoY); Crysvita $481M, Dojolvi $96M, Evkeeza $59M.
Q4 net loss $129M ($1.29/share); full year net loss $575M ($5.83/share).
Restructuring: 10% workforce cut (~130 employees), $50M charges; path to profitability in 2027.
2026 revenue guidance $730-760M; combined R&D+SG&A expenses flat to down low-single digits.
UX111 BLA resubmitted; received Incomplete Response Letter requesting additional CMC documentation.

item 2.02 item 2.05 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Ultragenyx Pharmaceutical Inc. announced a restructuring with charges of approximately $50 million in total restructuring and restructuring-related charges affecting across the Company (10% workforce reduction of approximately 130 employees).

Type: restructuring
Charge: approximately $50 million in total restructuring and restructuring-related charges
Affected area: across the Company
Headcount: 10% workforce reduction of approximately 130 employees

Exact text from the filing

the Company is implementing a 10% workforce reduction of approximately 130 employees across the Company (the “RIF”). The Company began notifying affected employees on February 12, 2026, and expects this RIF to be substantially completed in the first half of 2026. The Company estimates that it will incur approximately $50 million in total restructuring and restructuring-related charges

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Ultragenyx Pharmaceutical Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-048738

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.